Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MTRR A66G polymorphism and breast cancer risk: a meta-analysis.

Breast cancer research and treatment - 1 Dec 2010

Hu Jia, Zhou Guo-Wu, Wang Ning, Wang Ya-Jie

Abstract excerpt

Methionine synthase reductase (MTRR) is one of the important enzymes involved in the folate metabolic pathway and its functional genetic polymorphisms may be associated with breast cancer risk. However, this relationship remains inconclusive. For better understanding the effect of MTRR A66G polymorphism on breast cancer risk, a meta-analysis was performed. By searching PubMed and EMBASE, a total of six...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asian People
Share to Breast Neoplasms
Share to Confidence Intervals

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ferredoxin-NADP Reductase

Share to Folic Acid

Share to Odds Ratio

Share to Risk Assessment

Share to White People

Source

Identifiers

PMID: 20411324
DOI: 10.1007/s10549-010-0892-1

Genes

MTRR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MTRR A66G polymorphism and breast cancer risk: a meta-analysis.PMID 20411324Read ↗

Methionine synthase reductase A66G polymorphism is not associated with breast cancer susceptibility - a meta-analysis.Semantic proximity Read ↗

Methionine synthase A2756G polymorphism and breast cancer risk: a meta-analysis involving 18,953 subjects.Semantic proximity Read ↗

Methionine synthase reductase A66G polymorphism contributes to tumor susceptibility: evidence from 35 case-control studies.Semantic proximity Read ↗

Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls.Semantic proximity Read ↗

Role of polymorphism of methyltetrahydrofolate-homocysteine methyltransferase (MTR) A2756G and breast cancer risk.Semantic proximity Read ↗

Methionine synthase A2756G polymorphism and breast cancer risk: an up-to-date meta-analysis.Semantic proximity Read ↗

Lack of association between MHTFR Glu429Ala polymorphism and breast cancer susceptibility: a systematic review and meta-analysis of 29 research studies.Semantic proximity Read ↗

Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk in Chinese population: a meta-analysis of 22 case-control studies.Semantic proximity Read ↗

MTHFR C677T polymorphism associated with breast cancer susceptibility: a meta-analysis involving 15,260 cases and 20,411 controls.Semantic proximity Read ↗

Association of folate metabolism-related genetic polymorphisms with susceptibility to breast cancer: A protocol for a systematic review and meta-analysis.Semantic proximity Read ↗

Methionine synthase A2756G polymorphism and cancer risk: a meta-analysis.Semantic proximity Read ↗

Lack of association between methylenetetrahydrofolate reductase gene A1298C polymorphism and breast cancer susceptibility.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.